The major respiratory players weighing up M&A options will have noted with interest that Verona Pharma plc, arguably the field's most attractive takeover target, has secured hundreds of millions of dollars as its closely watched chronic obstructive pulmonary disease (COPD) drug ensifentrine moves closer to US approval.
Key Takeaways
- Verona has raised $400m for its COPD candidate ensifentrine
- The drug has got a PDUFA date in June 2024
- The UK firm plans to go it
The UK company has entered into a debt financing facility providing it with access to up to $400m from funds managed by Oxford Finance and Hercules Capital. This could come in handy for the commercial launch of ensifentrine, which has been under review at the US Food and Drug Administration since late September last year. The financing replaces an existing $150m facility inked in October 2022 with Oxford
